Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease
暂无分享,去创建一个
A. Andoh | S. Bamba | Kenichiro Takahashi | Y. Fujiyama | Takehide Fujimoto | H. Imaeda | T. Tsujikawa | M. Sasaki
[1] L. Aarden,et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation , 2013, Annals of the rheumatic diseases.
[2] A. Cheifetz,et al. Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis , 2013, The American Journal of Gastroenterology.
[3] T. Matsui,et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan , 2012, Journal of Gastroenterology.
[4] T. Matsui,et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.
[5] M. Cottone,et al. Adalimumab in steroid‐dependent Crohn's disease patients: Prognostic factors for clinical benefit , 2012, Inflammatory bowel diseases.
[6] J. Gisbert,et al. Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.
[7] A. Andoh,et al. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease , 2012, Journal of Gastroenterology.
[8] G. Veres,et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[9] A. Ford,et al. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. , 2011, Journal of Crohn's & colitis.
[10] B. Dijkmans,et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.
[11] S. Hanauer,et al. Assessing Response and Loss of Response to Biological Therapies in IBD , 2011, The American Journal of Gastroenterology.
[12] L. Peyrin-Biroulet,et al. Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.
[13] W. Reinisch,et al. Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience , 2011, Alimentary pharmacology & therapeutics.
[14] S. Schreiber,et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.
[15] S. Plevy,et al. Dosage adjustment during long‐term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics , 2011, Inflammatory bowel diseases.
[16] D. Rubin,et al. Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents , 2010, Inflammatory bowel diseases.
[17] W. Sandborn,et al. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[18] P. Rutgeerts,et al. The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.
[19] P. Rutgeerts,et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.
[20] B. Dijkmans,et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. , 2009, Arthritis and rheumatism.
[21] S. Travis,et al. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.
[22] J. Gisbert,et al. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.
[23] E. Kuipers,et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.
[24] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[25] P. Rutgeerts,et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.
[26] B. Dijkmans,et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[27] P. Rutgeerts,et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.
[28] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[30] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[31] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.
[32] L. Mayer,et al. Evolving paradigms in the pathogenesis of IBD , 2009, Journal of Gastroenterology.
[33] G. D'Haens,et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .
[34] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.